Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 placebo-controlled crossover study of oral deucrictibant for on-demand treatment of hereditary angioedema attacks
NL-OMON60479Phase 3Completed
- Sponsor
- Pharvaris
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of deucrictibant in hereditary angioedema (HAE) (2 arms), sponsored by Pharvaris. Primary endpoint: Time to onset of symptom relief. Started Nov 2024; status: completed.
02
Drugs
deucrictibant
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on NL-OMON60479.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60479.